Revumenib + venetoclax/azacitidine in adults with newly diagnosed NPM1m or KMT2Ar acute leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002): Trial in progress

Abstract

Author

Huls G, et al.

Congress

European Hematology Association Annual Congress 2026

Stockholm, Sweden | June 11 – 14, 2026